Blue Fin Group is excited to add our voices to the conversation around Specialty Pharmacy—comment on this blog post to tell us what you think the hot topics will be at the Asembia Summit.Read Full Article
Welcome to the Blue Fin Group Information Library. Our consultants regularly publish white papers, case studies and articles, lead workshops, deliver speaking engagements, and share opinions on topics of interest to decision makers in the healthcare industry.
You don’t become an industry leader without having alot to say—click on the video vignettes below to hear our expert’s perspectives on a range of topics.
Blue Fin Group is often sought out as an expert commentator by industry publications — featuring our latest thinking and timely insights on the issues that matter most to the healthcare industry.
Blue Fin Group keeps a lens trained on many facets of the healthcare industry, and our white papers focus on singular topics that are relevant and timely. Known for our out-of-the-box thinking, these insights provide a deeper dive or different viewpoint from what others in the industry provide.
Case studies that show the transformation from challenge to solution. Each one details the existing situation, Blue Fin Group’s unique approach, the solution deployed, and the results achieved on behalf of the client. At Blue Fin Group, we deliver Deep Knowledge. Powerful Results.
Deep knowledge, unique insights and powerful perspectives focused on the healthcare industry, provided by Blue Fin Group associates.
As I write this, I am on my way to the Academy of Managed Care Pharmacy’s Annual Meeting in the Mile High city. This is my second year attending the event as a Blue Fin Group consultant. Last year, I had been at Blue Fin Group for just a week, so I primarily had the perspective […]Read Full Article
Clelia Biamonti, Senior Principal, shares insights on why it is still necessary to celebrate the achievements of women in this country and within our communities.Read Full Article
Orphan medications can treat populations with as few as one hundred patients or less in the US, and may come with high price tag. Payers and manufacturers are dealing with this dynamic in ways that are both similar and distinct. Phyllis Kidder, Principal Consultant, will speak on the topic of “Orphan and Rare Disease Products and Exclusive Pharmacy Networks” with Bill Roth, Founding Partner, this week at the sPCMA conference in Orlando, FL.Read Full Article
Jennifer Hamilton, Partner, reflects on attending the sPCMA Business Forum in Orlando, FL this week for the first time.Read Full Article
Today is Rare Disease Day. The NORD database lists over 1300 diseases and the global rare disease list (RARE List™) is comprised of about 7,000 different rare diseases affecting more than 300 million people worldwide. This is a day to build awareness, understanding and recognize the amazing patients and families that deal with these incredibly […]Read Full Article
Addressing these questions can help you take your patient support services strategy from “good to great”: Do the unique characteristics of your product, its patients and their prescribers truly warrant the need for support services? If so, which services should you provide and for how long? Right-fit services need to be based on analysis of […]Read Full Article
It’s such an amazing time to be working in healthcare from a market access, and more broadly, a commercialization perspective. We are seeing more and more innovative and transformative medicines come to market in therapeutic areas where such treatment did not exist before. We are seeing diseases that were once death sentences become chronic diseases […]Read Full Article